Skip to main content

High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer.

Publication ,  Journal Article
Peters, WP; Ross, M; Vredenburgh, JJ; Meisenberg, B; Marks, LB; Winer, E; Kurtzberg, J; Bast, RC; Jones, R; Shpall, E
Published in: J Clin Oncol
June 1993

PURPOSE: We studied high-dose cyclophosphamide, cisplatin, and carmustine (CPA/cDDP/BCNU) with autologous bone marrow support (ABMS) as consolidation after standard-dose adjuvant chemotherapy treatment of primary breast cancer involving 10 or more axillary lymph nodes. PATIENTS AND METHODS: One hundred two women with stage IIA, IIB, IIIA, or IIIB breast cancer involving 10 or more lymph nodes at surgery were registered; 85 were eligible, treated, and assessable. Patients were treated with four cycles of standard-dose cyclophosphamide, doxorubicin, and fluorouracil (CAF), followed by high-dose CPA/cDDP/BCNU with ABMS. RESULTS: Actuarial event-free survival for the study patients at a median follow-up of 2.5 years is 72% (95% confidence interval, 56% to 82%). Comparison to three historical or concurrent Cancer and Leukemia Group B (CALGB) adjuvant chemotherapy trials selected for similar patients showed event-free survival at 2.5 years to be between 38% and 52%. Therapy-related mortality was 12%; pulmonary toxicity of variable severity occurred in 31% of patients. Quality-of-life evaluations indicate that patients are functioning well without major impairments. CONCLUSION: High-dose consolidation with CPA/cDDP/BCNU and ABMS after standard-dose CAF results in a decreased frequency of relapse in patients with high-risk primary breast cancer compared with historical series at the median follow-up of 2.5 years. Evaluation in a prospective, randomized trial is warranted and currently underway.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Clin Oncol

DOI

ISSN

0732-183X

Publication Date

June 1993

Volume

11

Issue

6

Start / End Page

1132 / 1143

Location

United States

Related Subject Headings

  • Transplantation, Autologous
  • Survival Rate
  • Oncology & Carcinogenesis
  • Middle Aged
  • Humans
  • Fluorouracil
  • Female
  • Doxorubicin
  • Cyclophosphamide
  • Combined Modality Therapy
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Peters, W. P., Ross, M., Vredenburgh, J. J., Meisenberg, B., Marks, L. B., Winer, E., … Shpall, E. (1993). High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. J Clin Oncol, 11(6), 1132–1143. https://doi.org/10.1200/JCO.1993.11.6.1132
Peters, W. P., M. Ross, J. J. Vredenburgh, B. Meisenberg, L. B. Marks, E. Winer, J. Kurtzberg, R. C. Bast, R. Jones, and E. Shpall. “High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer.J Clin Oncol 11, no. 6 (June 1993): 1132–43. https://doi.org/10.1200/JCO.1993.11.6.1132.
Peters WP, Ross M, Vredenburgh JJ, Meisenberg B, Marks LB, Winer E, et al. High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. J Clin Oncol. 1993 Jun;11(6):1132–43.
Peters, W. P., et al. “High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer.J Clin Oncol, vol. 11, no. 6, June 1993, pp. 1132–43. Pubmed, doi:10.1200/JCO.1993.11.6.1132.
Peters WP, Ross M, Vredenburgh JJ, Meisenberg B, Marks LB, Winer E, Kurtzberg J, Bast RC, Jones R, Shpall E. High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. J Clin Oncol. 1993 Jun;11(6):1132–1143.

Published In

J Clin Oncol

DOI

ISSN

0732-183X

Publication Date

June 1993

Volume

11

Issue

6

Start / End Page

1132 / 1143

Location

United States

Related Subject Headings

  • Transplantation, Autologous
  • Survival Rate
  • Oncology & Carcinogenesis
  • Middle Aged
  • Humans
  • Fluorouracil
  • Female
  • Doxorubicin
  • Cyclophosphamide
  • Combined Modality Therapy